Log in to search using one of your social media accounts:

 

Cell-free DNA integrity for the monitoring of breast cancer: Future perspectives?
Abstract Breast cancer (BC) is the most common cancer and the second cause of death in women worldwide. Therapeutic options are increasing, but the response to treatments is not always efficient and the risk of recurrence covers decades. In this perspective, the need to have a proper follow-up for the therapeutic responses and for anticipating recurrence it is urgent in the clinical setting. Liquid biopsy provides the basic principle for a non-invasive method for the routinely monitoring of BC. However, due to the heterogeneity of tumors during onset and progression, the search for tumor DNA mutations of targeted ...
Source: Clinical Breast Cancer - April 10, 2018 Category: Cancer & Oncology Authors: Sobhani N, Generali D, Zanconati F, Bortul M, Scaggiante B Tags: World J Clin Oncol Source Type: research

Clinicopathological predictors of long-term benefit in breast cancer treated with neoadjuvant chemotherapy.
Abstract AIM: To investigate the survival impact of clinicopathological factors, including pathological complete response (pCR) and tumor-infiltrating lymphocytes (sTIL) levels according to subtypes, in breast cancer (BC) patients who received neo-adjuvant chemotherapy (NAC). METHODS: We evaluated 435 BC patients who presented and received NAC at the Instituto Nacional de Enfermedades Neoplasicas from 2003 to 2014. sTIL was analyzed as the proportion of tumor stroma occupied by lymphocytes, and was prospectively evaluated on hematoxylin and eosin-stained sections of the preNAC core biopsy. pCR was considered ...
Source: Clinical Breast Cancer - April 10, 2018 Category: Cancer & Oncology Authors: Galvez M, Castaneda CA, Sanchez J, Castillo M, Rebaza LP, Calderon G, Cruz M, Cotrina JM, Abugattas J, Dunstan J, Guerra H, Mejia O, Gomez HL Tags: World J Clin Oncol Source Type: research

Women's Free-text Comments on their Quality of Life: An Exploratory Analysis from the UK Standardisation of Breast Radiotherapy (START) Trials for Early Breast Cancer.
CONCLUSIONS: Difficult personal circumstances and other health concerns affected many women's PROM ratings at 5 years of follow-up, in addition to ongoing cancer treatment effects. Greater attention to multiple sources of distress and adversity could facilitate personalised care and aid interpretation of PROMs. PMID: 29653749 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 10, 2018 Category: Cancer & Oncology Authors: Mills J, Haviland JS, Moynihan C, Bliss JM, Hopwood P, START Trial Management Group Tags: Clin Oncol (R Coll Radiol) Source Type: research

Iron-dependent cell death as executioner of cancer stem cells.
Abstract This commentary highlights the findings by Mai, et al. that ironomycin, derivatives of salinomycin, exhibited more potent and selective therapeutic activity against breast cancer stem cells by accumulating and sequestering iron in lysosome, followed by an iron-mediated lysosomal production of reactive oxygen species and an iron-dependent cell death. These unprecedented findings identified iron homeostasis and iron-mediated processes as potentially druggable in the context of cancer stem cells. PMID: 29636068 [PubMed - in process] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 10, 2018 Category: Cancer & Oncology Authors: Zhao B, Li X, Wang Y, Shang P Tags: J Exp Clin Cancer Res Source Type: research

Evaluation of waiting times for breast cancer diagnosis and surgical treatment.
CONCLUSIONS: Delays in diagnosis and surgery in the case of women diagnosed on the basis of symptoms may be improved. There is a temporary tendency to a greater delay in surgery. Some clinical and biological factors must be taken into account to optimise delays. Survival results are not adversely affected by delays. PMID: 29633184 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 9, 2018 Category: Cancer & Oncology Authors: Baena-Cañada JM, Rodríguez-Pérez L, Gámez-Casado S, Quílez-Cutillas A, Cortés-Carmona C, Rosado-Varela P, Estalella-Mendoza S, Ramírez-Daffós P, Jaén-Olasolo J, Benítez-Rodríguez E Tags: Clin Transl Oncol Source Type: research

Type 1 diabetes mellitus and risk of cancer: a meta-analysis of observational studies.
Conclusion: This meta-analysis suggests that type 1 diabetes is associated with the increased risk of several types of cancer and the decreased risk of breast cancer. However, the plausible mechanisms for the decreased risk of breast cancer remain unclear. Further prospective studies with proper adjustment for possible confounding factors are warranted. PMID: 29635473 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 9, 2018 Category: Cancer & Oncology Authors: Sona MF, Myung SK, Park K, Jargalsaikhan G Tags: Jpn J Clin Oncol Source Type: research

ZMYND8 acetylation mediates HIF-dependent breast cancer progression and metastasis.
Abstract Altered epigenetic reprogramming contributes to breast cancer progression and metastasis. How the epigenetic reader mediates breast cancer progression remains poorly understood. Here, we showed that the epigenetic reader zinc finger MYND-type containing 8 (ZMYND8) is induced by HIF-1 and HIF-2 in breast cancer cells and also upregulated in human breast tumors, and is correlated with poor survival of patients with breast cancer. Genetic deletion of ZMYND8 decreases breast cancer cell colony formation, migration, and invasion in vitro, and inhibits breast tumor growth and metastasis to the lungs in mice. Th...
Source: Clinical Breast Cancer - April 9, 2018 Category: Cancer & Oncology Authors: Chen Y, Zhang B, Bao L, Jin L, Yang M, Peng Y, Kumar A, Wang JE, Wang C, Zou X, Xing C, Wang Y, Luo W Tags: J Clin Invest Source Type: research

Fertility Preservation in Patients With Cancer: ASCO Clinical Practice Guideline Update.
Abstract Purpose To provide current recommendations about fertility preservation for adults and children with cancer. Methods A systematic review of the literature published from January 2013 to March 2017 was completed using PubMed and the Cochrane Library. An Update Panel reviewed the identified publications. Results There were 61 publications identified and reviewed. None of these publications prompted a significant change in the 2013 recommendations. Recommendations Health care providers should initiate the discussion on the possibility of infertility with patients with cancer treated during their reproductive...
Source: Clinical Breast Cancer - April 5, 2018 Category: Cancer & Oncology Authors: Oktay K, Harvey BE, Partridge AH, Quinn GP, Reinecke J, Taylor HS, Wallace WH, Wang ET, Loren AW Tags: J Clin Oncol Source Type: research

Breast Cancer Family History and Contralateral Breast Cancer Risk in Young Women: An Update From the Women's Environmental Cancer and Radiation Epidemiology Study.
Conclusion Breast cancer family history confers a high CBC risk, even after excluding women with deleterious mutations. Clinicians are urged to use detailed family histories to guide treatment and future screening decisions for young women with breast cancer. PMID: 29620998 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 5, 2018 Category: Cancer & Oncology Authors: Reiner AS, Sisti J, John EM, Lynch CF, Brooks JD, Mellemkjær L, Boice JD, Knight JA, Concannon P, Capanu M, Tischkowitz M, Robson M, Liang X, Woods M, Conti DV, Duggan D, Shore R, Stram DO, Thomas DC, Malone KE, Bernstein L, WECARE Study Collaborative Gr Tags: J Clin Oncol Source Type: research

Investigation of genotoxicity risk and DNA repair capacity in breast cancer patients using anastrozole.
Abstract OBJECTIVE: Breast cancer is the most common cancer in women worldwide and the incidence increases in postmenopausal women. Anastrozole is a non-steroidal (type II), third-generation aromatase inhibitor (AI) that is used in the treatment of postmenopausal estrogen-related breast cancer. Several studies have been conducted to assess the efficacy, safety, and superiority of AIs to tamoxifen; however, a literature search did not reveal a study that investigated the genotoxic potential of AIs. The aim of this study was to investigate the possible DNA damage risk profile and individual DNA repair capacity of pa...
Source: Clinical Breast Cancer - April 4, 2018 Category: Cancer & Oncology Authors: Devecioglu TY, Aydogan F, Omurtag GZ, Bese NS, Sardas S Tags: North Clin Istanb Source Type: research

Risk factors for breast cancer among Indian women: A case-control study.
Conclusions: Waist size and WHR are the major risk factors for carcinoma of breast. Adequate exercise and weight control are the most effective lifestyle changes that can reduce the risk of developing breast cancer. PMID: 29607854 [PubMed - in process] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 1, 2018 Category: Cancer & Oncology Authors: Antony MP, Surakutty B, Vasu TA, Chisthi M Tags: Niger J Clin Pract Source Type: research

Prognostic Impact of Weight Change During Adjuvant Chemotherapy in Patients With High-Risk Early Breast Cancer: Results From the ADEBAR Study.
CONCLUSION: Weight change of> 5% during adjuvant chemotherapy in patients with high-risk early breast cancer is associated with poor OS. PMID: 29598955 [PubMed - in process] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 1, 2018 Category: Cancer & Oncology Authors: Mutschler NS, Scholz C, Friedl TWP, Zwingers T, Fasching PA, Beckmann MW, Fehm T, Mohrmann S, Salmen J, Ziegler C, Jäger B, Widschwendter P, de Gregorio N, Schochter F, Mahner S, Harbeck N, Weissenbacher T, Jückstock J, Janni W, Rack B Tags: Clin Breast Cancer Source Type: research

Granular cell tumor in axillary region: A rare entity.
vá I Abstract A granular cell tumor (GCT), is a rare soft tissue tumor which may occur throughout the body, usually in the head and neck, skin or subcutaneous tissues of the trunk and upper extremities, and female genital region. A total of 5-8% of all cases of GCTs occur in the breast. GCT of the breast may mimic breast cancer both clinically and radiologically. GCTs are usually benign and solitary; however, approximately 2% occur as malignant tumors. Benign GCTs are treated with wide local excision and are associated with a good prognosis. The current case report presents findings in a patient with a beni...
Source: Clinical Breast Cancer - March 16, 2018 Category: Cancer & Oncology Authors: Pohlodek K, Jáni P, Mečiarová I Tags: Mol Clin Oncol Source Type: research

Baseline neutrophil-to-lymphocyte ratio predicts the prognosis of castration-resistant prostate cancer treated with abiraterone acetate.
Abstract Abiraterone acetate (AA), a CYP17 inhibitor, now has a crucial role in the treatment of castration-resistant prostate cancer (CRPC), and previous studies have reported several prognostic clinical factors for AA treatment. The neutrophil-to-lymphocyte ratio (NLR) has also been investigated for a CRPC treatments in a few reports, however it has not been identified to be a prognostic factor for AA treatment in Japanese patients. The present study aimed to assess the association of the baseline NLR with the overall survival (OS) in CPRC patients treated by AA. The present study retrospectively reviewed a tota...
Source: Clinical Breast Cancer - March 16, 2018 Category: Cancer & Oncology Authors: Yasui M, Hasegawa Y, Kawahara T, Kumano Y, Miyoshi Y, Matsubara N, Uemura H Tags: Mol Clin Oncol Source Type: research

Survival Analysis After Neoadjuvant Chemotherapy With Trastuzumab or Lapatinib in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the GeparQuinto (G5) Study (GBG 44).
Conclusion pCR correlated with long-term outcome. In patients with hormone receptor-positive tumors, prolonged anti-HER2 treatment-neoadjuvant lapatinib for 6 months, followed by adjuvant trastuzumab for 12 months-significantly improved survival compared with anti-HER2 treatment with trastuzumab alone. PMID: 29543566 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - March 15, 2018 Category: Cancer & Oncology Authors: Untch M, von Minckwitz G, Gerber B, Schem C, Rezai M, Fasching PA, Tesch H, Eggemann H, Hanusch C, Huober J, Solbach C, Jackisch C, Kunz G, Blohmer JU, Hauschild M, Fehm T, Nekljudova V, Loibl S, GBG and the AGO-B Study Group Tags: J Clin Oncol Source Type: research

Risk and Prognosis of Cancer After Lower Limb Arterial Thrombosis.
Conclusions -Lower limb arterial thrombosis was a marker of occult cancer, especially lung cancer, and was an adverse prognostic factor for mortality in common cancers. PMID: 29540440 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - March 14, 2018 Category: Cancer & Oncology Authors: Sundbøll J, Veres K, Horváth-Puhó E, Adelborg K, Sørensen HT Tags: Circulation Source Type: research

p95HER2 methionine 611 carboxy-terminal fragment is predictive of trastuzumab adjuvant treatment benefit in the FinHer trial.
CONCLUSIONS: p95 expression levels were prognostic in the chemotherapy-alone arm and predictive of trastuzumab treatment benefit in FinHer. These results warrant further investigation of p95 as a predictive marker of trastuzumab treatment benefit in the adjuvant setting. PMID: 29535130 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - March 13, 2018 Category: Cancer & Oncology Authors: Sperinde J, Huang W, Vehtari A, Chenna A, Kellokumpu-Lehtinen PL, Winslow J, Bono P, Lie Y, Petropoulos CJ, Weidler JM, Joensuu H Tags: Clin Cancer Res Source Type: research

Breast cancer histologic grading using digital microscopy: concordance and outcome association.
This study aims at investigating the agreement between BC grading using traditional light microscopy (LM) and digital WSI with consideration of reproducibility and impact on outcome prediction. METHODS: A large (n=1675) well-characterised cohort of BC originally graded by LM was re-graded using WSI. Two separate virtual-based grading sessions (V1 and V2) were performed with a 3-month washout period. Outcome was assessed using BC-specific and distant metastasis-free survival. RESULTS: The concordance between LM grading and WSI was strong (LM/WSI Cramer's V: V1=0.576, and V2=0.579). The agreement regarding grade co...
Source: Clinical Breast Cancer - March 13, 2018 Category: Cancer & Oncology Authors: Rakha EA, Aleskandarani M, Toss MS, Green AR, Ball G, Ellis IO, Dalton LW Tags: J Clin Pathol Source Type: research

Comparative analysis of the effect of different radiotherapy regimes on lymphocyte and its subpopulations in breast cancer patients.
Abstract PURPOSE: The aim of this study was to determine whether different radiotherapy (RT) fractionation schemes induce disparate effects on lymphocyte and its subsets in breast cancer patients. METHODS: 60 female patients diagnosed with breast cancer were recruited in this study after receiving modified radical mastectomy and were randomly divided into two groups. One group received irradiation at a standard dose of 50 Gy in 25 fractions and the other at a dose of 40.3 Gy in 13 fractions. Both total lymphocyte count and its composition were recorded at three timepoints: right before the radiation...
Source: Clinical Breast Cancer - March 13, 2018 Category: Cancer & Oncology Authors: Yuan C, Wang Q Tags: Clin Transl Oncol Source Type: research

Synchronous Detection of Male Breast Cancer and Prostatic Cancer in a Patient With Suspected Prostatic Carcinoma on 68Ga-PSMA PET/CT Imaging.
We report a case of 64-year-old man who presented with the history of lower urinary tract symptoms. The digital rectal examination revealed hard and nodular prostate, and serum prostate-specific antigen level was 23.4 ng/mL. Ga-labeled prostate-specific membrane antigen PET/CT revealed prostate-specific membrane antigen-expressing lesions in the prostate, axillary tail of the right breast, and axillary lymph nodes. Histology from prostate revealed prostate carcinoma, whereas fine-needle aspiration from the breast revealed invasive ductal carcinoma of the breast. PMID: 29538032 [PubMed - as supplied by publisher] (Sour...
Source: Clinical Breast Cancer - March 13, 2018 Category: Cancer & Oncology Authors: Kumar R, Mittal BR, Bhattacharya A, Singh H, Singh SK Tags: Clin Nucl Med Source Type: research

Telocytes in the female reproductive system: An overview of up-to-date knowledge.
Abstract Telocytes are emerging cell population localized in the stroma of numerous organs, characterized by a distinctive morphology - small cell body with very long, slender prolongations, termed telopodes. Those cells can be found in the whole female reproductive system: in the vagina, uterus, oviducts and ovaries, mammary glands and also in the placenta. In our review, we aim at complete and transparent revision of the current knowledge of telocytes' localization and function, enriched by the analysis of the possible future direction of development of their clinical applications. The function of telocytes in t...
Source: Clinical Breast Cancer - March 13, 2018 Category: Cancer & Oncology Authors: Janas P, Kucybała I, Radoń-Pokracka M, Huras H Tags: Adv Clin Exp Med Source Type: research

Gaps in Receipt of Clinically Indicated Genetic Counseling After Diagnosis of Breast Cancer.
Conclusion Less than one half (43.5%) of patients with clinical indications received formal genetic counseling. There is a large gap between mandates for timely pretest formal genetic counseling in higher-risk patients and the reality of practice today. PMID: 29528794 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - March 12, 2018 Category: Cancer & Oncology Authors: Katz SJ, Ward KC, Hamilton AS, Mcleod MC, Wallner LP, Morrow M, Jagsi R, Hawley ST, Kurian AW Tags: J Clin Oncol Source Type: research

US Food and Drug Administration Pooled Analysis to Assess the Impact of Bone-Only Metastatic Breast Cancer on Clinical Trial Outcomes and Radiographic Assessments.
Conclusion To our knowledge, this review is the largest analysis to date of the BO subgroup of MBC and suggests this subgroup may have a distinct natural history. There also seems to be a difference in how the local investigators assessed progression events in the BO subgroup when compared with the other two groups. PMID: 29522361 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - March 9, 2018 Category: Cancer & Oncology Authors: Wedam SB, Beaver JA, Amiri-Kordestani L, Bloomquist E, Tang S, Goldberg KB, Sridhara R, Ibrahim A, Kim G, Kluetz P, McKee A, Pazdur R Tags: J Clin Oncol Source Type: research

Type of second primary malignancy after achieving complete response by definitive chemoradiation therapy in patients with esophageal squamous cell carcinoma.
CONCLUSIONS: Because second primary malignancy developed often after achieving CR by dCRT for ESCC, it should be followed carefully. PMID: 29520523 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - March 8, 2018 Category: Cancer & Oncology Authors: Yamaguchi T, Kato K, Nagashima K, Iwasa S, Honma Y, Takashima A, Hamaguchi T, Ito Y, Itami J, Boku N, Higuchi K Tags: Int J Clin Oncol Source Type: research

Do FHIT gene alterations play a role in human solid tumors?
Abstract The fragile histidine triad (FHIT) gene encloses an active common chromosomal fragile site, FRA3B. This gene is known to be associated with genomic instability, apoptosis and DNA damage. FHIT disturbances have been related to carcinogenesis in different types of human tumor. Despite this, there are some controversies about the exact role of the FHIT gene in relation to tumor biology. Several pieces of evidence support the hypothesis that FHIT acts as a tumor suppressor gene. A loss or decrease in the Fhit protein expression appears to be related to tumor progression, poor prognostic factors and lower surv...
Source: Clinical Breast Cancer - March 8, 2018 Category: Cancer & Oncology Authors: Silveira Zavalhia L, Weber Medeiros A, Oliveira Silva A, Vial Roehe A Tags: Asia Pac J Clin Oncol Source Type: research

Impending Atypical Femoral Fracture in a Patient of Breast Cancer With Bone Metastases Receiving Long-term Denosumab.
We describe a 59-year-old woman with a history of breast carcinoma and bone metastasis who was prescribed denosumab for 4 years. The patient had no history of any prior bisphosphonate use. Bone scintigraphy showed an abnormal uptake in the right femur, which was confirmed as an impending AFF or atypical femoral stress reaction. In oncological patients receiving long-term denosumab, AFF should be included as a differential diagnosis for focal femoral findings.This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in...
Source: Clinical Breast Cancer - March 7, 2018 Category: Cancer & Oncology Authors: Sugihara T, Koizumi M, Hayakawa K, Ito Y, Sata N Tags: Clin Nucl Med Source Type: research

Long-term crude probabilities of death among breast cancer patients by age and stage: a population-based survival study in Northeastern Spain (Girona-Tarragona 1985-2004).
CONCLUSIONS: In our study, women diagnosed with breast cancer had higher long-term probability to die from breast cancer than from other causes. The improvements in treatment and the lead-time bias in detecting cancer in an early stage resulted in a reduction of 19% in the risk of death between diagnostic periods. PMID: 29511947 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - March 6, 2018 Category: Cancer & Oncology Authors: Clèries R, Ameijide A, Buxó M, Martínez JM, Marcos-Gragera R, Vilardell ML, Carulla M, Yasui Y, Vilardell M, Espinàs JA, Borràs JM, Galceran J, Izquierdo À Tags: Clin Transl Oncol Source Type: research

Breast cancer: Fibroblast subtypes alter the microenvironment.
PMID: 29508858 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - March 6, 2018 Category: Cancer & Oncology Authors: Sidaway P Tags: Nat Rev Clin Oncol Source Type: research

Genetic Variations, Exposure to Persistent Organic Pollutants and Breast Cancer Risk: A Greenlandic Case-Control Study.
This article is protected by copyright. All rights reserved. PMID: 29510000 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - March 6, 2018 Category: Cancer & Oncology Authors: Wielsøe M, Eiberg H, Ghisari M, Kern P, Lind O, Bonefeld-Jørgensen EC Tags: Basic Clin Pharmacol Toxicol Source Type: research

CADM2, as a new target of miR-10b, promotes tumor metastasis through FAK/AKT pathway in hepatocellular carcinoma.
CONCLUSIONS: Our study demonstrates that miR-10b-CADM2-FAK/AKT axis plays an important role in HCC metastasis, which might be a novel potential therapeutic option for HCC treatment. PMID: 29506532 [PubMed - in process] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - March 5, 2018 Category: Cancer & Oncology Authors: Li D, Zhang Y, Zhang H, Zhan C, Li X, Ba T, Qiu Z, E F, Lv G, Zou C, Wang C, Si L, Zou C, Li Q, Gao X Tags: J Exp Clin Cancer Res Source Type: research

Multiple primary non-breast tumors in breast cancer survivors.
CONCLUSIONS: Older age represents the major risk of developing a second primary non-breast cancer, excluding ovarian cancer. Clinical surveillance is required to prevent ovarian and thyroid cancers, respectively, in patients with positive family history, triple negative, G3 breast cancer and during hormonal therapy treatment in postmenopausal status. PMID: 29502170 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - March 3, 2018 Category: Cancer & Oncology Authors: Corso G, Veronesi P, Santomauro GI, Maisonneuve P, Morigi C, Peruzzotti G, Intra M, Sacchini V, Galimberti V Tags: J Cancer Res Clin Oncol Source Type: research

Frequency of BRCA1 and BRCA2 causative founder variants in ovarian cancer patients in South-East Poland.
Conclusions: The frequency of 13 causative founder variants in Podkarpacie was lower than in other regions of Poland. Testing of three BRCA1 mutations (c.5266dupC, c.181 T > G, c.676delT) should be considered a sensitive test panel. PMID: 29492181 [PubMed] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - March 2, 2018 Category: Cancer & Oncology Authors: Kluz T, Jasiewicz A, Marczyk E, Jach R, Jakubowska A, Lubiński J, Narod SA, Gronwald J Tags: Hered Cancer Clin Pract Source Type: research

Breast Cancer in Low- and Middle-Income Countries: Why We Need Pathology Capability to Solve This Challenge.
Abstract Breast cancer is the leading cause of cancer mortality among women in developing countries. Timely and accurate histopathological diagnosis of breast cancer is critical to delivering high-quality breast cancer care to patients in low- and middle-income countries (LMIC). The most important prognostic factors in breast cancer along with tumor size and nodal status are tumor grade, estrogen receptor status, as well as HER2 status in countries where specific targeted therapies are available. In addition, detailed and complete cancer registry data are needed to assess a country's disease burden and guide disea...
Source: Clinical Breast Cancer - February 9, 2018 Category: Cancer & Oncology Authors: Martei YM, Pace LE, Brock JE, Shulman LN Tags: Clin Lab Med Source Type: research

Core Needle Biopsy of the Breast: An Evaluation of Contemporary Data.
This article highlights contemporary diagnostic criteria and outcome data that would support an evidence-based approach to the management of these nonmalignant lesions of the breast diagnosed on CNB. PMID: 29413652 [PubMed - in process] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - February 9, 2018 Category: Cancer & Oncology Authors: Calhoun BC Tags: Surg Pathol Clin Source Type: research

Lobular Carcinoma In Situ.
Abstract Lobular carcinoma in situ (LCIS) is a risk factor and a nonobligate precursor of breast carcinoma. The relative risk of invasive carcinoma after classic LCIS diagnosis is approximately 9 to 10 times that of the general population. Classic LCIS diagnosed on core biopsy with concordant imaging and pathologic findings does not mandate surgical excision, and margin status is not reported. The identification of variant LCIS in a needle core biopsy specimen mandates surgical excision, regardless of radiologic-pathologic concordance. The presence of variant LCIS close to the surgical margin of a resection specim...
Source: Clinical Breast Cancer - February 9, 2018 Category: Cancer & Oncology Authors: Wen HY, Brogi E Tags: Surg Pathol Clin Source Type: research

Ancillary Prognostic and Predictive Testing in Breast Cancer: Focus on Discordant, Unusual, and Borderline Results.
Abstract Ancillary testing in breast cancer has become standard of care to determine what therapies may be most effective for individual patients with breast cancer. Single-marker tests are required on all newly diagnosed and newly metastatic breast cancers. Markers of proliferation are also used, and include both single-marker tests like Ki67 as well as panel-based gene expression tests, which have made more recent contributions to prognostic and predictive testing in breast cancers. This review focuses on pathologist interpretation of these ancillary test results, with a focus on expected versus unexpected resul...
Source: Clinical Breast Cancer - February 9, 2018 Category: Cancer & Oncology Authors: Allison KH Tags: Surg Pathol Clin Source Type: research

Genotype-Phenotype Correlations in Breast Cancer.
Abstract Only a few breast cancer histologic subtypes harbor distinct genetic alterations that are associated with a specific morphology (genotype-phenotype correlation). Secretory carcinomas and adenoid cystic carcinomas are each characterized by recurrent translocations, and invasive lobular carcinomas frequently have CDH1 mutations. Solid papillary carcinoma with reverse polarity is a rare breast cancer subtype with a distinctive morphology and recently identified IDH2 mutations. We review the clinical and pathologic features and underlying genetic alterations of those breast cancer subtypes with established ge...
Source: Clinical Breast Cancer - February 9, 2018 Category: Cancer & Oncology Authors: Marotti JD, Schnitt SJ Tags: Surg Pathol Clin Source Type: research

Processing and Reporting of Breast Specimens in the Neoadjuvant Setting.
Abstract Standardization of quantification of residual disease in the breast and lymph nodes with routine pathologic macroscopic and microscopic evaluation leads to accurate and reproducible measures of response to neoadjuvant treatment. Multidisciplinary collaboration and correlation of clinical, imaging, gross and microscopic findings is essential. The processing approach to post-neoadjuvant breast cancer surgical specimens and the elements needed in the pathology report are the same regardless of breast cancer subtype or type of neoadjuvant treatment. The residual cancer burden incorporates response in the brea...
Source: Clinical Breast Cancer - February 9, 2018 Category: Cancer & Oncology Authors: Bossuyt V Tags: Surg Pathol Clin Source Type: research

The Drug-Drug Interaction Profile of Presatovir.
This study enrolled 64 healthy subjects to evaluate the effect of cyclosporine, a P-gp, BCRP, and OATP1B1/1B3 inhibitor; rifampin, a strong CYP3A4 and P-gp inducer; efavirenz, a moderate CYP3A4 inducer; and cobicistat, a potent CYP3A inhibitor, on presatovir pharmacokinetics. Presatovir plasma exposures (maximum observed plasma concentration [Cmax ] and area under the plasma concentration-time curve from time 0 extrapolated to infinity [AUCinf ]) were not affected by coadministration of cyclosporine, suggesting presatovir is not a sensitive substrate of P-gp, BCRP, or OATP1B1/1B3. As expected, based on the role of CYP3A in...
Source: Clinical Breast Cancer - February 7, 2018 Category: Cancer & Oncology Authors: Xin Y, Weng W, Murray BP, Eisenberg EJ, Chien JW, Ling J, Silverman JA Tags: J Clin Pharmacol Source Type: research

Breast cancer: Recurrent fusions in endocrine-resistant disease.
PMID: 29405202 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - February 6, 2018 Category: Cancer & Oncology Authors: Romero D Tags: Nat Rev Clin Oncol Source Type: research

Phosphatidylinositol 3-Kinase α-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study.
Conclusion Alpelisib demonstrated a tolerable safety profile and encouraging preliminary activity in patients with PIK3CA-altered solid tumors, supporting the rationale for selective PI3Kα inhibition in combination with other agents for the treatment of PIK3CA-mutant tumors. PMID: 29401002 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - February 5, 2018 Category: Cancer & Oncology Authors: Juric D, Rodon J, Tabernero J, Janku F, Burris HA, Schellens JHM, Middleton MR, Berlin J, Schuler M, Gil-Martin M, Rugo HS, Seggewiss-Bernhardt R, Huang A, Bootle D, Demanse D, Blumenstein L, Coughlin C, Quadt C, Baselga J Tags: J Clin Oncol Source Type: research

Germline promoter hypermethylation in BRCA1 and BRCA2 genes is not present in hereditary breast cancer patients.
CONCLUSIONS: Despite the results achieved at somatic levels by other researchers, these were not confirmed in our study at the germline level. Our results show the need to establish more predictive CpG sites in the BRCA promoter regions to optimize the MS-MLPA assay for the detection of germline hypermethylation as an effective pre-screening tool for whole-BRCA genetic analysis in HBOC, because we can not rule out the existence of germline promoter hypermethylation in BRCA. PMID: 29404838 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - February 5, 2018 Category: Cancer & Oncology Authors: Rodríguez-Balada M, Roig B, Melé M, Salvat M, Martorell L, Borràs J, Gumà J Tags: Clin Transl Oncol Source Type: research

Predictive factors of satisfaction and quality of life after immediate breast reconstruction using the BREAST-Q ©.
CONCLUSIONS: The type of treatment and lymphedema modify the patients' quality of life. Nicotine dependence is associated with lower satisfaction with the breast and with the outcome. RELEVANCE TO CLINICAL PRACTICE: This study suggests the need for multi-disciplinary attention during the first year of adjuvant treatment despite the benefits of immediate reconstruction. It shows the need for preoperative assessment of the level of nicotine dependence, anxiety and depression of smoking patients before preoperative counseling. This article is protected by copyright. All rights reserved. PMID: 29396899 [PubMed - as s...
Source: Clinical Breast Cancer - February 3, 2018 Category: Cancer & Oncology Authors: Cereijo-Garea C, Pita-Fernández S, Acea-Nebril B, Rey-Villar R, García-Novoa A, Varela-Lamas C, Builes-Ramirez S, Seoane-Pillado T, Balboa-Barreiro V Tags: J Clin Nurs Source Type: research

Selenium in infant formula milk.
Abstract Formula-based animal milk is an alternative source of infant nutrition in many cases when breastfeeding is unacceptable or inaccessible; however, these replacements often have low selenium levels. The composition of infant formula milk should be as close as possible to that of human breast milk, both in content and chemical speciation. Selenium is an essential trace element for infants. Generally, human breast milk is the ideal food to ensure adequate infant Se intake. However, to date, sodium selenite or sodium selenate has been used as selenium supplementation in infant formula milk in most countries. T...
Source: Clinical Breast Cancer - February 1, 2018 Category: Cancer & Oncology Authors: He MJ, Zhang SQ, Mu W, Huang ZW Tags: Asia Pac J Clin Nutr Source Type: research

Label-Free Quantitative Proteomic Screening of Candidate Plasma Biomarkers for the Prognosis of Breast Cancer with Different Lymph Node Statuses.
CONCLUSIONS AND CLINICAL RELEVANCE: The present dataset provides a list of candidate biomarkers that could be used for early differentiation diagnosis and prognosis of breast cancer with lymph node metastasis. This article is protected by copyright. All rights reserved. PMID: 29384592 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - January 31, 2018 Category: Cancer & Oncology Authors: Chen L, Zhao W, He J, Li L, Meng D, Cai D, Yu J, Chen D, Wu Y, Zhou T Tags: Proteomics Clin Appl Source Type: research

Risk of Synchronous Distant Recurrence at Time of Locoregional Recurrence in Patients With Stage II and III Breast Cancer (AFT-01).
Conclusion These findings support current recommendations for systemic imaging in the setting of locoregional recurrence, particularly for patients with lymph node or chest wall recurrences. Because most patients with isolated locoregional recurrence will be recommended locoregional treatment, early identification of distant metastases through routine systemic imaging may spare them treatments unlikely to extend their survival. PMID: 29384721 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - January 31, 2018 Category: Cancer & Oncology Authors: Neuman HB, Schumacher JR, Francescatti AB, Adesoye T, Edge SB, Vanness DJ, Yu M, McKellar D, Winchester DP, Greenberg CC, Alliance/American College of Surgeons Clinical Research Program Cancer Care Delivery Research Breast Cancer Surveillance Working Grou Tags: J Clin Oncol Source Type: research

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy.
Abstract Tamoxifen is biotransformed by CYP2D6 to 4-hydroxytamoxifen and 4-hydroxy N-desmethyl tamoxifen (endoxifen), both with greater antiestrogenic potency than the parent drug. Patients with certain CYP2D6 genetic polymorphisms and patients who receive strong CYP2D6 inhibitors exhibit lower endoxifen concentrations and a higher risk of disease recurrence in some studies of tamoxifen adjuvant therapy of early breast cancer. We summarize evidence from the literature and provide therapeutic recommendations for tamoxifen based on CYP2D6 genotype. PMID: 29385237 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - January 31, 2018 Category: Cancer & Oncology Authors: Goetz MP, Sangkuhl K, Guchelaar HJ, Schwab M, Province M, Whirl-Carrillo M, Symmans WF, McLeod HL, Ratain MJ, Zembutsu H, Gaedigk A, van Schaik RH, Ingle JN, Caudle KE, Klein TE Tags: Clin Pharmacol Ther Source Type: research

Efficacy of management strategies for aromatase inhibitor-induced arthralgia in breast cancer patients: a systematic review.
Abstract Aromatase inhibitors are the gold standard in the treatment of hormone receptor-positive breast cancer, but lead to an arthralgia syndrome which is implicated in 13-22% of noncompliance. This is the first systematic review of the efficacy of existing management strategies for this side effect. Eligible studies were retrieved from computer searches of Medline, Cochrane and Embase and the significant intervention groups were identified. The risk of bias of selected studies was evaluated and the relevant data items were extracted, summarized and analyzed. A total of 21 studies were discussed in this review r...
Source: Clinical Breast Cancer - January 30, 2018 Category: Cancer & Oncology Authors: Nahm N, Mee S, Marx G Tags: Asia Pac J Clin Oncol Source Type: research

Genetic variants of prospectively demonstrated phenocopies in BRCA1/2 kindreds.
Conclusion: All women in breast or breast/ovarian cancer kindreds would benefit from being offered genetic testing irrespective of which causative genetic variants have been demonstrated in their relatives. PMID: 29371908 [PubMed] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - January 28, 2018 Category: Cancer & Oncology Authors: Dominguez-Valentin M, Evans DGR, Nakken S, Tubeuf H, Vodak D, Ekstrøm PO, Nissen AM, Morak M, Holinski-Feder E, Martins A, Møller P, Hovig E Tags: Hered Cancer Clin Pract Source Type: research

Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer.
Conclusion Enzalutamide demonstrated clinical activity and was well tolerated in patients with advanced AR-positive TNBC. Adverse events related to enzalutamide were consistent with its known safety profile. This study supports additional development of enzalutamide in advanced TNBC. PMID: 29373071 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - January 26, 2018 Category: Cancer & Oncology Authors: Traina TA, Miller K, Yardley DA, Eakle J, Schwartzberg LS, O'Shaughnessy J, Gradishar W, Schmid P, Winer E, Kelly C, Nanda R, Gucalp A, Awada A, Garcia-Estevez L, Trudeau ME, Steinberg J, Uppal H, Tudor IC, Peterson A, Cortes J Tags: J Clin Oncol Source Type: research